Avecia and EnPlusOne agree to evaluate enzymatic RNA manufacturing
Company / institutional announcement · Nitto Denko Avecia
Source published: · Event / reporting date: 2026-11-05
Site published: 2026-11-06 · Updated: 2026-11-06
This source is linked automatically. Choose a question to get started.
What changed
Nitto Denko Avecia and EnPlusOne signed an evaluation agreement for the ezRNA enzymatic synthesis platform. The phased program covers proof-of-concept studies, laboratory process evaluation, and technology transfer at Avecia facilities. The platform uses a water-based, template-free process. The agreement evaluates manufacturing feasibility; it does not announce a completed commercial manufacturing contract or a definitive platform license.
Why it may matter
Analysis: The evaluation may generate practical scale-up and transfer data for modified oligonucleotides, with commercial adoption dependent on demonstrated manufacturing performance.
The interpretation above is analysis, not a conclusion attributed to the original source.
Read the original source ↗Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections